Researchers within the Astbury Centre have a number of distinctive capabilities, and by working closely with its industry advisory board, the hub has been able to match these to market need, to maximise opportunities for commercialising such expertise.

As a result, there are five areas of particular focus: inhibiting protein-protein interactions, targeted molecular delivery, predicting and preventing biopharmaceutical aggregation, ion channels research and translational drug discovery.

Research priorities

Multiple systems have been developed capable of delivering reagents with control of pharmacokinetics and biodistribution. This allows the delivery of reagents including RNAi to large proteins for applications in therapeutics, imaging and/or diagnostics.

Experimental and computational approaches are combined to understand, predict and control the properties of biological molecules.

A range of approaches has been developed to modulate protein-protein interactions, both with designed small molecules and biomolecular probes.

Research focussing on understanding normal human functioning and the mechanisms of disease is applied to numerous ion channel types with impact on multiple diseases.

Novel, primarily small molecule, agents have been developed at Leeds to modulate disease pathways in multiple therapeutic areas.